URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902
24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with
placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up
to 48 weeks post-dose.